4.7 Review

Current and upcoming therapies to modulate skin scarring and fibrosis

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 146, Issue -, Pages 37-59

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2018.08.009

Keywords

Hypertrophic scars; Keloid; Scleroderma; Systemic sclerosis; Myofibroblasts; Scarring; Collagen synthesis; Collagen deposition; Inflammation; Wound healing; Remodelling

Funding

  1. Health Research Board, Health Research Awards Programme [HRA_POR/2011/84]
  2. Science Foundation Ireland, Career Development Award Programme [15/CDA/3629]
  3. Science Foundation Ireland
  4. European Regional Development Fund [13/RC/2073]
  5. EU H2020, ITN award, Tendon Therapy Train Project [676338]

Ask authors/readers for more resources

Skin is the largest organ of the human body. Being the interface between the body and the outer environment, makes it susceptible to physical injury. To maintain life, nature has endowed skin with a fast healing response that invariably ends in the formation of scar at the wounded dermal area. In many cases, skin remodelling may be impaired, leading to local hypertrophic scars or keloids. One should also consider that the scarring process is part of the wound healing response, which always starts with inflammation. Thus, scarring can also be induced in the dermis, in the absence of an actual wound, during chronic inflammatory processes. Considering the significant portion of the population that is subject to abnormal scarring, this review critically discusses the state-of-the-art and upcoming therapies in skin scarring and fibrosis. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available